Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Highlights
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Creative Biolabs is one of the world’s leading contract organizations (CRO) that has extensive experience in preclinical drug discovery. Our employees are at the core of our success, with the ambition to improving health and increasing access to quality health solutions worldwide. We believe when curious, courageous and collaborative people like you are brought together, a big difference will be made for the development of innovate medicines.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Suitable for use in FuncS, IF, Neut, ELISA, FC, IP, ICC and most other immunological methods.
CAS
1365267-33-9
Specific Activity
GPC3 (glypican 3) [Homo sapiens]
Protein Construction
"RG7686 is a first in class monoclonal humanized anti-glypican 3 antibody being developed as single agent and in combination againstmetastatic hepatocellular carcinoma. Its therapeutic activity in pre-clinical models was shown to take place via antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP)." – Roche pipelinegamma1 heavy chain (1-445) [humanized VH (Homo sapiens IGHV1-46*01 (82.70%) – (IGHD) – IGHJ5*02) [8.8.8] (1-115) – Homo sapiensIGHG1*01 (CH1 (116-213, hinge (214-228), CH2 (229-338), CH3 (339-443), CHS (444-445)) (116-445)], (218-219')-disulfide withkappa light chain (1'-219') [humanized V-KAPPA (Homo sapiens IGKV2-28*01 (86.00%) -IGKJ2*01) [11.3.9] (1'-112') – Homo sapiens IGKC*01(113'-219')]; dimer (224-224":227-227") – bisdisulfide
Purity
>95.0%, determined by analysis by RP-HPLC & analysis by SDS-PAGE.
BACKGROUND
Antigen Description
This gene encodes an enzyme with hydroxypyruvate reductase, glyoxylate reductase, and D-glycerate dehydrogenase enzymatic activities. The enzyme has widespread tissue expression and has a role in metabolism. Type II hyperoxaluria is caused by mutations in this gene.
Function
heparan sulfate proteoglycan binding; peptidyl-dipeptidase inhibitor activity; protein binding;